Global Information
회사소개 | 문의 | 비교리스트

뇌전증 치료제 시장 : 성장, 동향, 예측

Epilepsy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

리서치사 Mordor Intelligence LLP
발행일 2020년 06월 상품 코드 921243
페이지 정보 영문
US $ 4,250 ₩ 5,117,000 PDF (Single User License)
US $ 4,750 ₩ 5,719,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,224,000 PDF (Site License)
US $ 7,500 ₩ 9,030,000 PDF (Corporate License)

뇌전증 치료제 시장 : 성장, 동향, 예측 Epilepsy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
발행일 : 2020년 06월 페이지 정보 : 영문

세계 뇌전증 치료제 시장의 주요 성장요인으로는 지난 몇년간의 신약 승인 증가, 뇌전증 사례 증가, 세계적인 건강상태에 관한 인식 향상 등을 들 수 있습니다.

세계의 뇌전증 치료제(Epilepsy Drugs) 시장에 대해 조사했으며, 시장 기회 및 동향, 성장 촉진요인 및 억제요인, 치료제/유통채널/지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.


제1장 서론

  • 조사 결과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 지난 몇년간의 신약 승인 증가
    • 뇌전증 사례 증가
    • 세계적인 뇌전증에 대한 인식 향상
  • 시장 성장 억제요인
    • 약물 관련 부작용
    • 주요 브랜드의 최근 특허 만료
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 치료제별
    • 제1세대
    • 제2세대
    • 제3세대
  • 유통채널별
    • 병원 약국
    • 약국
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Abbott Laboratories
    • GlaxoSmithKline PLC
    • Johnson & Johnson Health Care Systems Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • UCB SA,

제7장 시장 기회 및 향후 동향

LSH 20.04.06

The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years and increasing cases of epilepsy across the globe.

Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. There is also rising awareness levels about epilepsy coupled with strategic alliances that are anticipated to stimulate the market growth. One of the organization Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.

Key Market Trends

Second Generation Anti-epileptics is the Segment by Drugs Expected to Hold a Large Market Share Over the Forecast Period

The second-generation Anti-epileptics drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.

Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018, one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer's disease. About one percent of Americans have some form of epilepsy, and nearly four percent (1 in 26) will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson's disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the epilepsy drug market.

Furthermore, there are various organizations making awareness about epilepsy in the United States. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.

Competitive Landscape

The market studied is a consolidated market owing to the presence of few major market players. Therefore most of the key players are found focusing on the expansion of their businesses to increase their market share. Also, they are adopting certain strategies, such as new product development, mergers, and acquisitions.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the New Drug Approvals over the Past Few Years
    • 4.2.2 Increase in the Cases of Epilepsy
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated With the Drugs
    • 4.3.2 Recent Patent Expiration of Major Brands
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drugs
    • 5.1.1 First Generation Anti-epileptics
    • 5.1.2 Second Generation Anti-epileptics
    • 5.1.3 Third Generation Anti-epileptics
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacy
    • 5.2.2 Pharmacy Stores
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Novartis AG
    • 6.1.5 Pfizer, Inc.
    • 6.1.6 Sanofi SA
    • 6.1.7 Sunovion Pharmaceuticals Inc.
    • 6.1.8 Takeda Pharmaceutical Company Limited
    • 6.1.9 UCB S.A.,


Back to Top
전화 문의